NO20085362L - Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet - Google Patents

Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet

Info

Publication number
NO20085362L
NO20085362L NO20085362A NO20085362A NO20085362L NO 20085362 L NO20085362 L NO 20085362L NO 20085362 A NO20085362 A NO 20085362A NO 20085362 A NO20085362 A NO 20085362A NO 20085362 L NO20085362 L NO 20085362L
Authority
NO
Norway
Prior art keywords
humanized anti
reduced immunogenicity
blocking antibodies
affinity human
function blocking
Prior art date
Application number
NO20085362A
Other languages
English (en)
Inventor
Dieter Zopf
Jorg Willuda
Stefan Steidl
Josef Prassler
Andreas Menrad
Klaus Bosslet
Heike Petrul
Corinne Petit-Frere
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of NO20085362L publication Critical patent/NO20085362L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Sammendrag Den foreliggende oppfinnelse vedrører rekombinante, humane eller humaniserte polypeptider som binder a5ß1-integrin med høy affinitet og blokkerende funksjon. Videre er diagnostiske og farmasøytiske anvendelser av polypeptidene beskrevet.
NO20085362A 2006-05-24 2008-12-22 Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet NO20085362L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24
PCT/EP2007/004648 WO2007134876A2 (en) 2006-05-24 2007-05-21 HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY

Publications (1)

Publication Number Publication Date
NO20085362L true NO20085362L (no) 2009-02-23

Family

ID=38659612

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085362A NO20085362L (no) 2006-05-24 2008-12-22 Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet

Country Status (23)

Country Link
US (1) US20090081207A1 (no)
EP (1) EP2032605A2 (no)
JP (1) JP2009537158A (no)
KR (1) KR20090027218A (no)
CN (1) CN101495515A (no)
AR (1) AR061107A1 (no)
AU (1) AU2007253586A1 (no)
BR (1) BRPI0711796A2 (no)
CA (1) CA2652886A1 (no)
CL (1) CL2007001488A1 (no)
CR (1) CR10456A (no)
DO (2) DOP2007000101A (no)
EA (1) EA200802348A1 (no)
EC (1) ECSP088909A (no)
MA (1) MA30425B1 (no)
MX (1) MX2008014910A (no)
NO (1) NO20085362L (no)
PE (1) PE20080100A1 (no)
TN (1) TNSN08469A1 (no)
TW (1) TW200817433A (no)
UY (1) UY30362A1 (no)
WO (1) WO2007134876A2 (no)
ZA (1) ZA200810850B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
ES2547421T3 (es) 2005-10-31 2015-10-06 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar el cáncer
MY159375A (en) 2006-03-21 2016-12-30 Genentech Inc Combinatorial therapy
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
CA2714071A1 (en) * 2008-02-05 2009-08-13 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
AU2009313389A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
AU2009331528A1 (en) * 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
EP2411411B1 (en) 2009-03-25 2016-08-31 F.Hoffmann-La Roche Ag Novel anti-alpha5beta1 antibodies and uses thereof
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2933262B1 (en) * 2010-07-09 2018-05-02 Affibody AB Polypeptides
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
TWI586378B (zh) 2012-03-13 2017-06-11 瑞斯比維特有限公司 新穎醫藥調配物
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
AU2013370467B2 (en) * 2012-12-26 2018-10-04 Oncosynergy, Inc. Anti- integrin beta1 antibody compositions and methods of use thereof
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR20180012832A (ko) * 2015-06-28 2018-02-06 올제네시스 바이오테라퓨틱스 아이엔씨. 혈관신생 억제용 융합 단백질
WO2021015336A1 (ko) * 2019-07-24 2021-01-28 가톨릭대학교 산학협력단 αVβ3 인테그린 표적 단일 도메인 항체
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
KR20110140143A (ko) * 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
EP1755659B1 (en) * 2004-03-24 2011-11-02 Abbott Biotherapeutics Corp. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
MY159375A (en) * 2006-03-21 2016-12-30 Genentech Inc Combinatorial therapy

Also Published As

Publication number Publication date
MA30425B1 (fr) 2009-05-04
DOP20070101A (es) 2007-12-30
TNSN08469A1 (en) 2010-04-14
ZA200810850B (en) 2010-05-26
WO2007134876A3 (en) 2008-03-27
KR20090027218A (ko) 2009-03-16
MX2008014910A (es) 2009-01-23
BRPI0711796A2 (pt) 2011-12-06
ECSP088909A (es) 2008-12-30
EA200802348A1 (ru) 2009-08-28
WO2007134876A2 (en) 2007-11-29
TW200817433A (en) 2008-04-16
AU2007253586A1 (en) 2007-11-29
US20090081207A1 (en) 2009-03-26
EP2032605A2 (en) 2009-03-11
PE20080100A1 (es) 2008-04-18
UY30362A1 (es) 2008-01-02
JP2009537158A (ja) 2009-10-29
CA2652886A1 (en) 2007-11-29
WO2007134876A8 (en) 2009-07-02
DOP2007000101A (es) 2007-12-31
CL2007001488A1 (es) 2008-01-04
AR061107A1 (es) 2008-08-06
CN101495515A (zh) 2009-07-29
CR10456A (es) 2009-02-26

Similar Documents

Publication Publication Date Title
NO20085362L (no) Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
EA201100694A1 (ru) Антитело к cd38 человека и его применение
ECSP12012272A (es) Proteínas que se unen al tnf-?
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
PE20131465A1 (es) Moleculas de union a 4-1 bb
UA112416C2 (uk) Антитіло до fap і способи його застосування
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0520677A2 (pt) identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
MX347197B (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
ATE512988T1 (de) Antikörper gegen epcam und anwendungen davon
WO2011002968A3 (en) Polypeptides and method of treatment
EA201170353A1 (ru) Антитела против гепатита с и их применение
EA201001212A1 (ru) Лечение микробных инфекций
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
MX2009003300A (es) Vectores de rhinovirus recombinantes.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application